DCT startup looking to forge better community relationships nets a modest Series B
The decentralized clinical trial industry went through a huge boom during the Covid-19 pandemic as biotechs and Big Pharma companies alike were forced to shift gears. Looking to capitalize on that momentum, a San Francisco startup is raising funds to ensure closer partnerships with the communities DCTs serve.
Curebase pulled together a $40 million Series B on Thursday, roughly 13 months after closing its Series A. While on the surface this may seem like another DTC company, CEO Tom Lemberg tells Endpoints News the company is looking to separate itself from the pack by going straight to the community to bring greater diversity to clinical trials.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters